📊 NKTX Key Takeaways
Is Nkarta, Inc. (NKTX) a Good Investment?
Nkarta is a pre-revenue biotech company with zero commercialized products, burning $28.2M quarterly in operations against only $27.4M cash reserves. At current burn rates, the company faces immediate capital runway risk and is entirely dependent on successful clinical development and equity financing to survive.
Nkarta remains pre-revenue with persistent operating losses and significant cash burn, offering no clear line-of-sight to profitability. While the balance sheet shows strong liquidity and no debt, reported cash and equivalents appear low relative to the burn rate, elevating funding and dilution risk.
Nkarta, Inc. Key Strengths (NKTX)
- Strong balance sheet with $285.9M stockholders' equity exceeding total assets of $372.1M
- Excellent liquidity position with 12.96x current ratio, indicating no near-term solvency risk if capital needs are met
- Zero debt burden eliminates interest obligations and financial covenant risk
- High current ratio indicating strong liquidity
- No long-term debt and modest liabilities
- Large equity base supporting near-term operations
NKTX Stock Risks: Nkarta, Inc. Investment Risks
- Zero revenue with no commercialized products; company remains in clinical/development stage
- Critical cash runway: $27.4M cash remaining with -$28.2M quarterly operating cash burn equates to ~3 months of operations
- Severe operating losses of -$30.9M and net losses of -$27.8M indicate R&D-intensive model with no offsetting revenue
- Complete dependence on successful clinical outcomes and capital markets for equity financing
- Negative free cash flow of -$28.6M indicates value destruction and inability to self-fund operations
- No revenue and sustained net losses
- High operating cash burn raising dilution/financing risk
- Clinical and regulatory execution risk typical of development-stage biotech
Key Metrics to Watch
- Quarterly cash burn rate and cash position relative to operating runway
- Clinical trial milestones and regulatory pathway progression
- Capital raises and financing events to extend operational runway
- Cash runway (cash + short-term investments vs operating burn)
- Clinical trial milestones and partnership funding
Nkarta, Inc. (NKTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.96x current ratio provides a solid financial cushion.
NKTX Profit Margin, ROE & Profitability Analysis
NKTX vs Healthcare Sector: How Nkarta, Inc. Compares
How Nkarta, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nkarta, Inc. Stock Overvalued? NKTX Valuation Analysis 2026
Based on fundamental analysis, Nkarta, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nkarta, Inc. Balance Sheet: NKTX Debt, Cash & Liquidity
NKTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nkarta, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.60 indicates the company is currently unprofitable.
NKTX Revenue Growth, EPS Growth & YoY Performance
NKTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $115.0K | -$2.7M | N/A |
| Q2 2020 | $2.3K | -$3.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nkarta, Inc. Dividends, Buybacks & Capital Allocation
NKTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nkarta, Inc. (CIK: 0001787400)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NKTX
What is the AI rating for NKTX?
Nkarta, Inc. (NKTX) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NKTX's key strengths?
Claude: Strong balance sheet with $285.9M stockholders' equity exceeding total assets of $372.1M. Excellent liquidity position with 12.96x current ratio, indicating no near-term solvency risk if capital needs are met. ChatGPT: High current ratio indicating strong liquidity. No long-term debt and modest liabilities.
What are the risks of investing in NKTX?
Claude: Zero revenue with no commercialized products; company remains in clinical/development stage. Critical cash runway: $27.4M cash remaining with -$28.2M quarterly operating cash burn equates to ~3 months of operations. ChatGPT: No revenue and sustained net losses. High operating cash burn raising dilution/financing risk.
What is NKTX's revenue and growth?
Nkarta, Inc. reported revenue of $0.0.
Does NKTX pay dividends?
Nkarta, Inc. does not currently pay dividends.
Where can I find NKTX SEC filings?
Official SEC filings for Nkarta, Inc. (CIK: 0001787400) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NKTX's EPS?
Nkarta, Inc. has a diluted EPS of $-0.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NKTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Nkarta, Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NKTX stock overvalued or undervalued?
Valuation metrics for NKTX: ROE of -9.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NKTX's AI grade for 2026?
Our dual AI analysis gives Nkarta, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NKTX's free cash flow?
Nkarta, Inc.'s operating cash flow is $-28.2M, with capital expenditures of $413.0K.
How does NKTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -9.7% (avg: 15%), current ratio 12.96 (avg: 2).